Welcome to our dedicated page for Enovis Corporation news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis Corporation stock.
Enovis Corporation (NYSE: ENOV) is a prominent player in the medical technology industry, dedicated to developing innovative solutions that improve patient outcomes and streamline healthcare workflows. Headquartered in Wilmington, DE, Enovis focuses on manufacturing and distributing high-quality medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy.
The company operates through two primary segments: Prevention & Recovery (P&R) and Reconstructive (Recon). The Prevention & Recovery segment, which generates the bulk of Enovis' revenue, is known for its extensive range of products aimed at injury prevention and patient rehabilitation. The Reconstructive segment offers advanced solutions for joint reconstruction surgeries, including knee, hip, and shoulder replacements.
Recent Achievements and Projects:
- Enovis recently announced the offering of $400 million in Convertible Senior Notes due 2028, aimed at financing the acquisition of LimaCorporate S.p.A., enhancing their global footprint in orthopedic solutions.
- The company's third-quarter 2023 financial results showcased a stable performance with revenues between $414 and $418 million, reflecting an 8-9% increase from the previous year.
- Enovis continues to innovate, showcasing new technologies such as the Evolve34™ Lapidus Correction System and the EF1 External Fixation product line at the ACFAS annual meeting.
Enovis is committed to a culture of continuous improvement, leveraging its global talent and innovative capabilities to develop products that drive measurable patient outcomes. The company's dedication to excellence is evident in its comprehensive portfolio, which includes the DJO, LLC subsidiary known for its contributions to the foot and ankle care continuum.
In addition to its robust product development pipeline, Enovis is actively engaged in strategic acquisitions to enhance its market position and product offerings. The company's financial outlook for 2024 is positive, with expected revenues approximating $2.06-2.16 billion and adjusted EBITDA forecasted to be $368-383 million.
For more information, visit the Enovis Corporation website.
Enovis (NYSE: ENOV), a medical technology growth company, has announced its participation in three upcoming investor conferences:
- Canaccord Genuity 44th Annual Growth Conference on August 13th
- Wells Fargo Healthcare Conference on September 5th
- Baird 2024 Global Healthcare Conference on September 11th
The company's management team, including CFO Ben Berry and CEO Matt Trerotola, will participate in fireside chats at these events. Live audio webcasts and replays will be available on Enovis' website under the Investors tab. Enovis is dedicated to developing clinically differentiated solutions for better patient outcomes and improved workflows in orthopedics and beyond.
Enovis (NYSE: ENOV) reported strong Q2 2024 results with 23% sales growth to $525 million and adjusted EBITDA margin expansion of 190 basis points to 17.2%. The company saw 60% reported growth in Recon and 2% in P&R. Despite a net loss of $0.34 per share, adjusted earnings were $0.62 per share. Enovis received FDA clearances for Arvis 2.0 Shoulder and Altivate Reverse Glenoid system, opened a Business Technology Center in Lisbon, and a new manufacturing facility in San Daniele. The company narrowed its 2024 revenue guidance to $2.08-$2.13 billion, reaffirmed adjusted EBITDA expectations of $368-$383 million, and raised adjusted EPS guidance to $2.62-$2.77.
Enovis (NYSE: ENOV), a medical technology growth company, has announced a time change for its Second Quarter 2024 results conference call. The call will now take place on August 7, 2024, at 8:00 a.m. Eastern Time, earlier than previously scheduled. The date and other details remain unchanged. Investors can access the live webcast through the Enovis website. For call participation, U.S. callers should dial (833) 685-0901, while international callers should use (412) 317-5715. A presentation related to the call will be available on ir.enovis.com, and a replay link will be provided on the website later that day.
Enovis (NYSE: ENOV), a medical technology growth company, has announced its upcoming second quarter 2024 financial results conference call. The event is scheduled for Wednesday, August 7, 2024, at 8:30 a.m. Eastern Time. An earnings press release will be issued earlier that morning, and a related presentation will be available on the company's investor relations website.
Investors can access the live webcast through the Enovis website. For those participating via phone, the dial-in numbers are (833) 685-0901 for U.S. callers and (412) 317-5715 for International callers. Participants should request to join the Enovis call. A replay of the call will be made available on the company's website later that day.
Enovis™ (NYSE: ENOV) has launched the AltiVate Reverse® Glenoid System, enhancing its market-leading AltiVate Reverse line. This new system, which received FDA 510(k) clearance in May 2024, offers modular, augmented baseplates and bone-sparing options, aiming to broaden the range of patients suitable for reverse shoulder arthroplasty. The first surgery using this system was performed by Dr. Mark Frankle at Tampa General Hospital on July 8, 2024. The system includes neutral and 15° wedge options, various central compression screw lengths, and four new glenospheres to optimize patient outcomes. Reverse shoulder arthroplasty accounts for over 60% of the 200,000+ annual shoulder replacements in the U.S., highlighting the growing demand for versatile implants. Enovis continues to prioritize surgeon-driven innovation and patient care through its comprehensive and efficient solutions.
Enovis (ENOV) will participate in upcoming investor conferences with its management team. Ben Berry, CFO, will be at the Bank of America Healthcare Conference on May 15th, and CEO Matt Trerotola will be at the William Blair Growth Stock Conference on June 4th. The webcasts and replays will be accessible on the Company's website.
Enovis (NYSE: ENOV) announced strong first-quarter 2024 financial results with a 27% sales growth on a reported basis, net sales of $516 million, and adjusted EBITDA of $83 million. The company reported a net loss of $1.32 per share but adjusted earnings per diluted share of $0.50. Enovis highlighted the acquisition of Lima, new product launches, and an improved 2024 financial outlook.
FAQ
What is the current stock price of Enovis Corporation (ENOV)?
What is the market cap of Enovis Corporation (ENOV)?
What does Enovis Corporation specialize in?
What are the main operating segments of Enovis?
What recent acquisitions has Enovis made?
How did Enovis perform financially in the third quarter of 2023?
What new technologies has Enovis recently introduced?
What is the financial outlook for Enovis in 2024?
What is the purpose of Enovis' recent offering of Convertible Senior Notes?
How does Enovis contribute to patient outcomes?
What is the significance of the Prevention & Recovery segment for Enovis?
Who are the key contacts for investor and media relations at Enovis?
